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ABSTRACT
Overexpression and/or hyperactivation of cyclin-dependent kinases (CDKs) are 
common features of most cancer types. CDKs have been shown to play important roles 
in tumor cell proliferation and growth by controlling cell cycle, transcription, and RNA 
splicing. CDK4/6 inhibitor palbociclib has been recently approved by the FDA for the 
treatment of breast cancer. CDK11 is a serine/threonine protein kinase in the CDK 
family and recent studies have shown that CDK11 also plays critical roles in cancer 
cell growth and proliferation. A variety of genetic and epigenetic events may cause 
universal overexpression of CDK11 in human cancers. Inhibition of CDK11 has been 
shown to lead to cancer cell death and apoptosis. Significant evidence has suggested 
that CDK11 may be a novel and promising therapeutic target for the treatment of 
cancers. This review will focus on the emerging roles of CDK11 in human cancers, 
and provide a proof-of-principle for continued efforts toward targeting CDK11 for 
effective cancer treatment.
INTRODUCTION
Malignant diseases are characterized by 
uncontrolled cell proliferation and growth [1]. Currently, 
surgery, radiotherapy, and chemotherapy are still the main 
modalities in the treatment of cancer [2-4]. Chemotherapy, 
as one of the basic treatment strategies, is applied in most 
cancer therapies. However, cancers usually have innate or 
acquired ability to develop resistance to many anti-cancer 
drugs, especially in the late stages [5, 6]. Additionally, 
most conventional chemotherapy drugs applied in the 
clinic are non-specific cytotoxic agents and will cause 
serious adverse effects to patients, thus identifying and 
developing novel therapeutic strategies is an urgent need 
for cancer treatment.
Cyclin-dependent kinases (CDKs) are serine/
threonine kinases that play a critical role in the 
regulation of cell cycle progression, as well as cellular 
transcription. Distinct CDKs are activated upon binding 
with their corresponding cyclin partners. Each kinase in 
this family is coordinated in an orchestrated way, and 
responsible for particular aspects of the cellular events. 
Aberrant expression or altered activity of distinct CDK 
complexes results in escape of cells from the cell cycle 
control and leads to malignant transformation. Therefore, 
the inhibition of CDKs in malignant cells provides 
a promising approach in the defense against cancer. 
Recently, many selective CDK inhibitors targeting specific 
CDKs were developed, which represent promising anti-
cancer drugs due to their strong anti-proliferative efficacy 
combined with a relative low direct cytotoxicity [7-
14]. Notably, palbociclib (IBRANCE®), a dual CDK4/6 
inhibitor, recently received accelerated approval by the 
Food and Drug Administration (FDA) for clinical breast 
cancer treatment due to its potent and selective inhibitory 
effect on estrogen receptor (ER) positive/human epidermal 
growth factor receptor 2 (HER2) negative breast cancer 
[15-18]. These developments suggest a promising 
application of CDK inhibitors as a novel therapeutic 
strategy in the treatment of human cancer.
CDK11 is a serine/threonine protein kinase in the 
CDK family. CDK11 also plays a crucial role in cancer 
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Table 1:  Members of CDK family and their functions in cancers
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cell proliferation and growth. Recent studies have found 
that the overexpression and activation of CDK11 is crucial 
in the growth and proliferation of cancer cells, including 
breast cancer, multiple myeloma, osteosarcoma, and other 
types of cancer, which has suggested that CDK11 may be 
a novel potential therapeutic target [19-22]. In this review, 
we discuss the specificity of CDK11 functions, regulation, 
and interactions in cancers, as well as the potential of 
targeting CDK11 in cancer treatment. 
THE BIOLOGY AND DEREGULATION OF 
CDKS IN HUMAN CANCERS
CDKs are a family of serine/threonine (Ser/Thr) 
protein kinases, composed of a catalytic kinase subunit 
and a regulatory cyclin subunit, which play crucial roles 
in cell cycle progression and transcriptional regulation 
in response to extracellular and intracellular signals 
[23]. CDKs are characterized by requirement of protein 
cyclin subunits for enzymatic activity, even though some 
CDKs can also play other roles without the involvement 
of cyclins [24]. Until now, based on the sequence 
similarity and nomenclature, the human CDKs family 
include members from CDK1 to CDK20 with specific 
or redundant roles in many aspects of cell growth and 
proliferation [25]. The evolutionary relationships among 
these CDK subfamilies have been identified [26]. 
Generally, CDKs are divided into cell cycle-
related subfamilies and transcription-related subfamilies 
in regard to their sequencing and main functional roles 
[26]. Classical cell cycle CDKs, including CDK1, CDK2, 
CDK4, and CDK6, mainly regulate the transitions 
between different phases of the cell cycle [27-29]. The 
cyclin C-CDK3 complex helps the cells to efficiently exit 
the G0 state and enter the G1 phase. In addition, CDK5, 
CDK11, CDK14, CDK15, CDK16, CDK17, and CDK18 
also belong to the cell cycle-related CDK subfamilies, 
which play different functional roles by regulating diverse 
cell cycle progress [30-38] (Table 1). On the other hand, 
transcription-related CDKs subfamilies function mainly 
via influencing transcription by phosphorylating the 
carboxy-terminal domain (CTD) of RNA polymerase 
II (RNAP II), which contains 52 tandem repeats of the 
consensus heptapeptide amino acid sequence (YSPTSPS) 
[39, 40]. Specifically, the transcription-related CDKs 
subfamilies are comprised of CDK7, CDK8, CDK9, 
CDK11, CDK12, CDK13, CDK19, and CDK20, which 
participate in different transcription regulation and exert 
diverse cellular functions [27, 39-49] (Table 1). 
In malignant cells, altered expression of CDKs and 
their modulators, including overexpression of cyclins 
and loss of expression of CDK inhibitors, results in 
deregulated CDK activity, providing a selective growth 
advantage. In human cancers, owing to various genetic 
and epigenetic events, CDKs are often overexpressed and/
or overactive, bringing about loss of checkpoint integrity 
and ultimately resulting in uncontrolled cell proliferation 
[27, 50-53]. For example, the cyclin D/CDK4/CDK6/RB 
pathway is hyperactive in various malignancies, such as 
melanoma, glioblastoma, osteosarcoma, lymphomas, 
breast and cervical cancers, squamous cell cancer, etc [54]. 
In the transcriptional CDK subfamily CDK9, aberrant 
activation has also been observed in several primary 
tumors, including myeloma, prostate cancer, and lung 
cancer [55].
Because of their critical roles in cell cycle 
progression and cellular transcription, as well as in 
the deregulation of human cancer, CDKs comprise 
an attractive set of targets for novel anticancer drug 
development [27]. The best known example is the recently 
FDA-approved CDK4/6 inhibitor palbociclib as the initial 
endocrine-based therapy for postmenopausal women 
with ER+/HER2- metastatic breast cancer. Among other 
members of the CDK family, CDK11 is involved in both 
cell cycle control and RNA transcription regulation. 
Figure 1: Schematic diagram of the full length CDK11 protein kinase. CDK11 is composed of an N-terminal regulatory 
region, which has multiple nuclear localization signals (NLS) and a 14-3-3 consensus site, and a carboxy-terminal (C-terminal) catalytic 
domain that is responsible for its kinase activity. There are two separate domains, an RE domain and a poly-E domain located in the center 
of the CDK11 protein. The full-length CDK11p110 isoform contains an IRES and a caspase-3 site, which leads to the generation of a larger 
CDK11p58 and a smaller CDK11p46 isoform, respectively (adapted from Trembley et. al., 2004.). NLS, nuclear localization signal; RE, 
arginine (R) and glutamic (E) acid residues; IRES, internal ribosomal entry site.
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CDK11 is functionally relevant to many biologic 
processes, such as RNA transcription and splicing, mitosis, 
autophagy, and apoptosis [38, 45, 47, 56, 57]. Recently, 
distinct and unique biologic roles of CDK11 have been 
discovered in human cancers and in other human diseases 
[58]. 
DISTINCT SPECIFICITY OF CDK11
Unlike other CDKs encoded only by a single gene, 
CDK11, formerly known as PITSLRE, is encoded by 
two highly homologous genes, CDC2L1 (also known 
as CDK11B) and CDC2L2 (also known as CDK11A, 
nonexistent in mouse) in humans. These two genes are 
localized in a genomic region that spans about 140 kb on 
human chromosome 1 band p36.3 [59]. In mouse, there 
is only one gene encoding CDK11 [25]. In human, both 
of the CDC2L genes contain 20 exons and 19 introns that 
encode almost identical protein kinases named CDK11A 
and CDK11B. 
CDK11 is composed of an N-terminal regulatory 
region, which has multiple nuclear localization signals 
(NLS) and a 14-3-3 consensus site, and a carboxy-terminal 
(C-terminal) catalytic domain that is responsible for its 
kinase activity [40, 60]. There are two separate domains, 
an arginine/glutamic acid domain (RE domain) and a 
poly-glutamic acid domain (poly-E domain) located in 
the center of the CDK11 protein (Figure 1) [40]. The RE 
domains are linked to association with RNA processing 
factors and poly-E domains are emerging as potential 
cytoskeletal interacting domains that support RE domain 
function and aide in keeping these proteins subnuclear. 
The most important conserved amino acids in CDK11 
are the PSTAIRE-helix and three phosphorylation sites, 
which are involved in the activation and repression of 
CDK kinase activity [40].
CDK11 binds to L-type cyclins and participates 
in the coordination between transcription and RNA 
processing, particularly alternative splicing [61]. The 
functions of CDK11 have been proved to be linked with 
RNA transcription and processing, regulation of cell cycle, 
neuronal function, and apoptosis [38, 40, 47, 56, 58]. The 
potential for CDK11 to regulate these diverse cellular 
activities is unique in the CDK family and highlights 
that CDK11 may exert critical regulatory roles in human 
tumorigenesis and malignant characteristics of cancer 
cells.
DIFFERENT ISOFORMS OF CDK11
 Due to the distinct structure and alterative RNA 
splicing, the CDC2L gene can produce three different 
CDK11 isoforms, a larger 110 kDa protein isoform, a 
mitosis-specific 58 kDa isoform, and a smaller apoptosis-
specific 46 kDa isoform (Table 2). The larger CDK11p110 
isoform is coded by the full-length CDK11 mRNA and 
contains an internal ribosome entry site (IRES), which 
leads to the generation of the CDK11p58 isoform during 
the G2/M phase of the cell cycle. In response to apoptotic 
signaling, both CDK11p110 and CDK11p58 isoforms 
can be cleaved by caspases 1 and 3 and produce the 
smaller CDK11p46 isoform (Figure 1) [62-64]. These 
different protein kinase isoforms play diverse cellular 
functions, including RNA transcription and processing, 
mitosis, and apoptosis. The larger CDK11p110 kinase is 
ubiquitously and constantly expressed throughout the 
cell cycle. Using subcellular fractionation techniques, 
the CDK11p110 isoform is proven to be a nuclear protein, 
which localizes to both splicing factor compartments and 
to the nucleoplasm [65]. On the other hand, the CDK11p58 
protein is specifically translated from an internal ribosome 
entry site and expressed transiently only in the G2/M 
phase of the cell cycle [66]. Due to the fact that CDK11p58 
is produced during a very narrow window of mitosis, 
it is much more difficult to detect than CDK11p110; its 
detection depends primarily on the mitotic characteristics 
of a particular cell type [40, 66]. Although CDK11p58 
shares the same sequences, including the kinase domain 
at the C-terminus of CDK11p110, the two isoforms possess 
different functions. The CDK11p110 isoform is mainly 
associated with RNA transcription and splicing [40, 45, 
60, 61, 67-69], while CDK11p58 isoform is involved in 
mitosis [70-77]. In contrast to CDK11p110 and CDK11p58, 
CDK11p46 localizes to the cytoplasm when ectopically 
expressed. Like other CDKs, the activation of CDK11 also 
needs to binding with special cyclins. Cyclins that bind 
Table 2: Biological characteristics of three main CDK11 isoforms
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CDK11p110, CDK11p58, and CDK11p46 are L-type cyclins, 
which are encoded by two cyclin L genes encoding a total 
of six isoforms [61]. CDK11p58 also binds cyclin D3 [78]. 
Several non-cyclin partners have also been proposed to 
interact with CDK11p46, such as eukaryotic initiation 
factor 3 p47 protein (eIF3 p47) and Ran-binding protein 
(RanBPM) [79, 80].
FUNCTIONS OF CDK11 IN NORMAL 
CELLS
The CDK11 null cells exhibit proliferative defects, 
mitotic arrest, and apoptosis, thus suggesting that 
CDK11 kinase is critical for embryonic development and 
Table 3: Characteristics of CDK11 interactiving partners
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cellular viability [73]. CDK11 knockout mice display an 
earlier lethality phenotype during the blastocyst stage of 
embryonic development. The larger CDK11p110 isoform, 
ubiquitously and constantly expressed throughout the 
cell cycle, is implicated in pre-mRNA splicing and 
transcription regulation by interacting with numerous 
proteins involved in the production of RNA transcripts 
during proliferation, including the largest subunit of 
RNA polymerase II and casein kinase II [81]. In addition, 
CDK11p110 has also been identified as a positive regulator 
of hedgehog signaling pathway [82, 83] as well as 
a modulator of the Wnt/β-catenin signaling cascade 
[84], both of which play vital roles in the regulation of 
embryonic development and adult homeostasis [85-87].
UPSTREAM AND DOWNSTREAM 
REGULATIONS IN CDK11 EXPRESSION 
AND FUNCTIONS
The upstream regulation of CDK11 expression 
has been studied to identify and characterize the CDK11 
promoters. As described above, CDK11 is encoded by 
two highly homologous genes known as CDC2L1 and 
CDC2L2. The CDC2L1 gene is regulated by a basal 
promoter region that is between nucleotides -152 and 
+11 of the 5’ region of the CDC2L1 gene while a region 
between nucleotides -145 and +10 of the 5’ region of 
CDC2L2 is confirmed to be critical for basal transcription 
of the CDC2L2 gene [88, 89]. In the promoter of the 
CDC2L1 gene, there are transcription factor binding sites 
for Ets-1 and Skn-1 that are necessary for CDC2L1 gene 
expression [88]. However, CDC2L2 gene expression is 
mainly regulated by Ets-1 and CREB [89]. 
 Checkpoint kinase 2 (CHK2) and casein kinase 
2 (CK2) are confirmed to be the upstream regulators 
in the CDK11 signaling pathway, which interact with 
CDK11 via phosphorylating the serine 737 and serine 
227 sites, respectively [67, 81, 90].CDK11 exerts its 
functional roles by regulating the expression and/or 
functions of downstream genes. However, the specific 
downstream signaling pathway mediated by CDK11 
has not been fully documented. Interestingly, a kinase 
siRNA screen identified CDK11 as a crucial regulator of 
the Hedgehog pathway [83]. CDK11 was confirmed to 
directly participate in the Hedgehog signaling pathway 
by functioning downstream of Smo and upstream of 
the Glioma-associated (Gli) transcription factors. More 
specifically, CDK11 interacts with the negative regulator 
Suppressor of Fused (Sufu) protein and relieves its 
inhibition of Gli, thus activating the Hedgehog signaling 
pathway, which is associated with developmental 
abnormalities and cancer [91, 92]. In addition, CDK11 
has also been proved to be a positive modulator of the 
Table 4:  Functions of CDK11 in different human cancers
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Wnt/β-catenin signaling cascade, whose dysregulation 
contributes to the development of cancer, using a kinase-
targeted high-throughput siRNA screen [84]. Nevertheless, 
the molecular mechanisms on which CDK11 regulate the 
Wnt/β-catenin signaling pathway remain unclear. 
CDK11 INTERACTING PROTEINS 
AND THE ROLES OF CDK11 IN 
TRANSCRIPTION AND RNA 
PROCESSING
The transcription process of mRNA requires the 
interaction of a set of general transcription factors and a 
wide range of gene-specific factors. The mediator complex 
is one type of large protein complexes, which play critical 
roles in RNA production and processing. Human mediator 
complex consists of RNAP II and several positive and 
negative transcription and RNA processing factors. 
CDK11 is proven to be a crucial part of the mediator 
complex. CDK11/cyclin L controls the assembly of the 
RNAP II mediator complex in fission yeast [69]. To be 
note, the absence of two conserved domains in the fission 
yeast CDK11 and cyclin orthologs and the reported 
essential roles of some CDK11 isoforms in unrelated 
processes in metazoans propose that CDK11 is essential 
for human beings gene transcription and processing [71, 
74, 76]. 
 In the regulation of RNA production, CDK11 could 
directly phosphorylate the CTD of RNAP II and regulates 
Figure 2: Interacting proteins with CDK11 in transcription and RNA processing. The currently identified CDK11 interacting 
proteins in the transcription and RNA processing are illustrated in this figure. Among which, the protein kinases CHK2 and CK2 activate 
CDK11 by phosphorylating the serine 737 and serine 227 sites of the CDK11 kinase, respectively. Cyclin L acts as a crucial protein partner 
of the CDK11p110 isoform, while cyclin D3 is essential for functioning for the CDK11p58 isoform. RNPSI, 9G8, ELL2, TFIIF, TFIIS, 
FACT, 14-3-3, and Hsp90 interact with and are subsequently phosphorylated by CDK11. On the other hand, RBM15B/OTT3 interacts 
with CDK11 as a competitor and antagonizes the positive effect of CDK11 in RNA spicing. Sufu can be negatively regulated by CDK11 
and relieve its inhibition on Gli, thus activating the Hedgehog signaling pathway. CHK2, checkpoint kinase 2; CK2, casein kinase 2; 
RNPS1, RNA-binding protein with serine-rich domain; ELL2, RNA polymerase elongation factor 2; TFIIF, transcription factor IIF; TFIIS, 
transcription factor IIS; FACT, facilitates chromatin transcription; RBM15B/OTT3, RNA binding motif protein 15 B; Hsp90, heat shock 
protein 90; Sufu, Suppressor of fused.
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transcription initiation and elongation as well as RNA 
processing. In addition, CDK11 also exert its roles in the 
regulation of transcription and/or transcript processing via 
interacting with numerous transcription regulators and 
RNA splicing factors.
Several CDK11 interacting protein partners have 
been identified in the transcription and RNA processing 
by implementing yeast two-hybrid interactive screens, 
tandem affinity purification, mass spectrometry analyses, 
immunoblot, and immunoprecipitation (Figure 2, Table 
3). The first noteworthy finding is that cyclins L1 and 
L2 have been well documented as critical cyclin partner 
proteins of CDK11, which is necessary for the activation 
of the CDK11p110 protein isoform [61]. In addition, 
CDK11 also interacts with splicing factors, such as RNA-
binding protein (RNPS1) and 9G8 [60, 65] , as well as 
multiple transcriptional initiation and elongation factors, 
including RNA polymerase elongation factor 2 (ELL2), 
transcription factor IIF (TFIIF), transcription factor IIS 
(TFIIS), and facilitates chromatin transcription (FACT) 
[45]. RNA binding motif protein 15 B (RBM15B/OTT3) 
has been shown to interact with CDK11 as a competitor 
and antagonizes the positive effect of CDK11 in splicing 
[68]. CDK11 exerts the biological functions in cell cycle 
and apoptosis by interacting with several protein partners, 
including 14-3-3 protein and heat shock protein 70/90 
(Hsp70/90) [93, 94]. 
 Currently, there is no specific CDK11 inhibitor, 
which impedes the CDK11-targeted cancer therapy 
testing in preclinical models. However, the identification 
and characterization of these CDK11 interactors may 
facilitate the understanding of the mechanisms underlying 
CDK11 functions, as well as the development of 
therapeutic strategies for cancer. Indeed, some inhibitors 
targeting these CDK11 interactors have been successfully 
developed and used in preclinical evaluation or clinical 
trials, which may provide novel candidate compounds 
for cancer therapy. For example, CX-4945, a potent and 
selective small molecule inhibitor of CK2 and a confirmed 
CDK11 interacting protein, has been investigated for the 
treatment of prostate cancer [95]. Another small molecular 
compound, AZD7762, a CHK1/CHK2 (another validated 
CDK11 partner) inhibitor, has been evaluated in the 
treatment in patients with advanced solid tumors [96]. 
EXPRESSION AND THERAPEUTIC 
POTENTIALS OF CDK11 IN DIFFERENT 
HUMAN CANCERS
 Due to their critical roles in the growth and 
proliferation of many types of human cancer, CDKs 
comprise an attractive set of targets for novel anticancer 
drugs development. Many CDKs inhibitors are 
currently being assessed in preclinical or in clinical 
trial investigations for cancer therapy; among them, a 
CDK4/6 selective inhibitor palbociclib has recently been 
approved for breast cancer treatment due to its selected 
and promising inhibitory effect on ER+/HER2- breast 
cancer [15-18]. CDK11 function is a critical regulator of 
cell cycle progression and RNA transcription, and recent 
studies have suggested that CDK11 also plays important 
roles in several types of human cancers (Table 4).
CDK11 IN BREAST CANCER
Recently, the expression and association of 
CDK11 in human breast cancer has been explored [21]. 
Immunohistochemical and Western blot assay have 
revealed that CDK11 is highly expressed in both breast 
tumor tissues and cell lines. Elevated CDK11 expression 
in breast cancer tissues significantly correlates with poor 
differentiation, and is also associated with advanced TNM 
stage and poor clinical prognosis for breast cancer patients. 
In vitro knockdown of CDK11 by siRNA significantly 
inhibits cell growth and migration, and dramatically 
induces apoptosis in breast cancer cells. Similar results 
have also been found almost simultaneously by another 
investigation group, which also showed that CDK11 
expression is essential for the maintenance of the 
aggressive characteristic of triple negative breast cancer 
(TNBC) [97]. Immunohistochemical analysis of TNBC 
patient tissues showed that 100% of tumors stained 
positive for CDK11 with high nuclear intensity compared 
to normal tissue. The Cancer Genome Atlas analysis by 
comparing basal to other breast cancer subtypes, and to 
normal breast tissues revealed statistically significant 
differences in CDK11 expression. Downregulation of 
CDK11 in breast cancer cells resulted in significant loss 
of cell viability and clonal survival, reduced CDK11 
relevant mRNA and protein expression, and induced 
cell death changes [97]. Furthermore, in vivo treatment 
with tenfibgen-siCDK11 nanocapsules caused MDA-
MB-231 xenograft tumor shrinkage, loss of proliferation, 
and decreased expression of targeted genes. These 
findings suggest that CDK11 is critical for the survival 
and proliferation of breast cancer cells, which highlight 
that CDK11 may be a promising target for therapeutic 
development in breast cancer.
CDK11 IN MULTIPLE MYELOMA
 A kinase-wide RNAi lethality study using high-
through kinome siRNA screening identified CDK11 as 
a vulnerable kinase in human multiple myeloma, which 
proposes that inhibition of CDK11 represents a uniquely 
targeted novel therapeutic strategy in human multiple 
myeloma [22]. To better define potential drug targets 
in myeloma disease, another investigation conducted 
a focused RNAi lethality screening and consistently 
found that CDK11 is a crucial survival gene in multiple 
myeloma [98]. To further assess CDK11 for myeloma-
selective vulnerability, the study evaluated the expression 
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of CDK11 in human multiple myeloma, and showed 
that CDK11 is significantly upregulated in expression 
in primary multiple myeloma tissues, as compared with 
normal human primary tissues. Collectively, CDK11 is 
overexpressed and functions as a critical survival gene in 
human multiple myeloma, which suggests that CDK11 
may represent a promising druggable target for human 
multiple myeloma therapy.
CDK11 IN OSTEOSARCOMA
 Osteosarcoma is the most common primary 
malignant tumor of bone. A kinase shRNA screening 
first identified CDK11 as essential for the survival of 
osteosarcoma cells [19]. Osteosarcoma cells display high 
levels of CDK11 expression, and CDK11 knockdown 
inhibited cell growth and induced apoptosis in 
osteosarcoma cells [19]. Moreover, immunohistochemical 
analysis showed that osteosarcoma patients with high 
CDK11 expression are associated with significantly 
shorter survival than patients with low CDK11 expression. 
Systemic in vivo administration of in vivo ready siRNA 
of CDK11 reduced tumor growth in an osteosarcoma 
subcutaneous xenograft model. Furthermore, a recent 
study using a novel robust and highly efficient genome 
editing tool, the clustered regularly interspaced short 
palindromic repeats-Cas9 (CRISPR-Cas9) system, to 
silence endogenous CDK11 DNA found that CDK11 
knockout significantly reduced osteosarcoma cell viability, 
proliferation, migration, invasion, and induced cell 
death [99]. All these results show that CDK11 signaling 
is essential in osteosarcoma cell growth and survival, 
further elucidating the regulatory mechanisms controlling 
the expression of CDK11 and ultimately indicate that 
developing a CDK11 inhibitor may provide therapeutic 
benefit against osteosarcoma.
CDK11 IN LIPOSARCOMA
 Similarly, the functional and therapeutic relevance 
of CDK11 as a putative target in liposarcoma, another type 
of mesenchymal tissue-originated malignancy, was also 
studied. Immunohistochemical analysis of liposarcoma 
tissue microarray (TMA) showed that CDK11 is highly 
expressed in liposarcoma tissues as compared with 
benign lipoma tissues. CDK11 knockdown by synthetic 
siRNA or lentiviral shRNA decreased cell proliferation 
and induced apoptosis in liposarcoma cells. Moreover, 
CDK11 knockdown enhanced the cytotoxic effect of 
doxorubicin in liposarcoma cells [20]. These results 
suggest that CDK11 may be a promising therapeutic target 
for liposarcoma treatment. Future studies on the signaling 
pathway and molecular mechanisms of CDK11 and cell 
growth in liposarcoma are required. 
CDK11 IN OTHER TYPE OF HUMAN 
CANCERS
 The pioneer studies has also confirmed that CDK11 
is ubiquitously expressed many human cancer cell 
lines, such as Jurkat, Cem C7, HeLa, HEK 293, K562, 
suggesting the potential functional roles of CDK11 in 
carcinogenesis [40, 100]. Furthermore, an unbiased 
high-throughput RNAi screening found that CDK11 is a 
positive modulator of the Wnt/β-catenin pathway in colon 
cancer [84]. In cervical cancer, CDK11 knockdown by 
RNAi in HeLa cells induced abnormal spindle assembly, 
mitotic arrest by checkpoint activation, and cell death [71]. 
More recently, by using novel CRISPR-based knockouts 
with RNAi technology, CDK11 has been identified is the 
crucial gene in cells lacking either the tuberous sclerosis 
complex 1 (TSC1) or TSC2, but not that of wild-type cells. 
Mutation or aberrant inhibition of the TSC complex is 
common in various human tumor cancers. Knockdown of 
CDK11 showed growth-inhibiting effects in mammalian 
TSC2-deficient cell lines, including human tumor-derived 
(AML) cells. TSC1 and TSC2, function together in an 
evolutionarily conserved protein complex that is a point 
of convergence for major cell signaling pathways that 
regulate mTOR complex 1 (mTORC1) [101]. 
Taken together, CDK11 is usually overexpressed 
and/or activated in several types of human malignancies, 
and the overexpression and/or hyperactivation is highly 
associated with poor outcomes in cancer patients. 
Consequently, CDK11 may present as a selective and 
specific target for cancer therapy. The downregulation 
of expression and activity of CDK11 may be a novel 
therapeutic modality in cancer treatment. 
CDK11 IN OTHER HUMAN DISEASES
In addition to human cancer, CDKs play important 
roles in other types of human diseases. Among them, 
CDK7, CDK9 and CDK13 have been found to be critical 
for HIV replication inside cells. However, the function of 
CDK11 remains largely unknown. Recently, CDK11 has 
been found to regulate the cleavage and polyadenylation 
(CPA) of all viral transcripts [102, 103]. CDK11 was found 
to be associated with the TREX/THOC, which recruited 
this kinase to DNA. Once at the viral genome, CDK11 
phosphorylated serines at position 2 in the CTD of RNAP 
II, which increased levels of CPA factors at the HIV 3’ 
end. Higher levels of CDK11 increased the length of HIV 
poly(A) tails and the stability of mature viral transcripts. 
These data suggests that CDK11 also plays an important 
role in the transcriptional regulation of HIV mRNA.
CONCLUSIONS
Significant evidences have shown that 
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overexpression and hyperactivation of CDKs are 
common in cancers, and targeting CDK has emerged 
as a highly promising therapeutic strategy. Specifically, 
overexpression of CDK11 has been shown to be associated 
with different cancers recently. As CDK11 has been found 
to play a crucial role in cancer cell proliferation and 
growth, CDK11 represents a promising target for novel 
anti-cancer drug development. 
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